Myriad Genetics, Inc. (MYGN) Shares Gap Down to $33.84
Myriad Genetics, Inc. (NASDAQ:MYGN) shares gapped down prior to trading on Friday . The stock had previously closed at $34.90, but opened at $33.84. Myriad Genetics shares last traded at $28.50, with a volume of 1984157 shares changing hands.
A number of research firms recently weighed in on MYGN. ValuEngine lowered shares of Myriad Genetics from a “buy” rating to a “hold” rating in a report on Thursday. Zacks Investment Research raised shares of Myriad Genetics from a “hold” rating to a “strong-buy” rating and set a $42.00 target price for the company in a report on Tuesday, October 17th. Morgan Stanley reissued an “underweight” rating and issued a $24.00 target price (up from $17.00) on shares of Myriad Genetics in a report on Friday, October 6th. Leerink Swann reissued a “market perform” rating and issued a $31.00 target price on shares of Myriad Genetics in a report on Monday, October 2nd. Finally, Stephens reissued an “overweight” rating and issued a $40.00 target price (up from $36.00) on shares of Myriad Genetics in a report on Friday, September 22nd. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $26.40.
The stock has a market capitalization of $1,968.94, a PE ratio of 26.84, a PEG ratio of 1.83 and a beta of 0.24. The company has a quick ratio of 1.26, a current ratio of 1.46 and a debt-to-equity ratio of 0.13.
Myriad Genetics (NASDAQ:MYGN) last released its earnings results on Tuesday, August 8th. The company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.04. Myriad Genetics had a return on equity of 9.67% and a net margin of 2.83%. The business had revenue of $200.50 million during the quarter, compared to the consensus estimate of $193.71 million. During the same period last year, the company earned $0.36 earnings per share. The business’s revenue for the quarter was up 7.5% compared to the same quarter last year. equities research analysts predict that Myriad Genetics, Inc. will post 1.04 earnings per share for the current fiscal year.
In other news, Director John T. Henderson sold 30,000 shares of Myriad Genetics stock in a transaction on Friday, September 1st. The stock was sold at an average price of $30.30, for a total transaction of $909,000.00. Following the completion of the sale, the director now directly owns 52,524 shares in the company, valued at $1,591,477.20. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 6.70% of the stock is currently owned by company insiders.
Several large investors have recently added to or reduced their stakes in the company. CS Mckee LP lifted its position in shares of Myriad Genetics by 0.3% during the second quarter. CS Mckee LP now owns 30,000 shares of the company’s stock worth $775,000 after purchasing an additional 100 shares during the last quarter. Municipal Employees Retirement System of Michigan lifted its position in shares of Myriad Genetics by 3.1% during the second quarter. Municipal Employees Retirement System of Michigan now owns 16,080 shares of the company’s stock worth $416,000 after purchasing an additional 490 shares during the last quarter. Aperio Group LLC lifted its position in shares of Myriad Genetics by 4.6% during the second quarter. Aperio Group LLC now owns 12,129 shares of the company’s stock worth $313,000 after purchasing an additional 534 shares during the last quarter. LeJeune Puetz Investment Counsel LLC lifted its position in shares of Myriad Genetics by 3.3% during the second quarter. LeJeune Puetz Investment Counsel LLC now owns 31,025 shares of the company’s stock worth $802,000 after purchasing an additional 1,000 shares during the last quarter. Finally, Teachers Advisors LLC lifted its position in shares of Myriad Genetics by 1.1% during the first quarter. Teachers Advisors LLC now owns 116,924 shares of the company’s stock worth $2,245,000 after purchasing an additional 1,287 shares during the last quarter.
Myriad Genetics Company Profile
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.